Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

BACKGROUND: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes. Newer agents such as Bevaciz...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, Dara O, Chambers, Gillian, O' Grady, Liam, Barry, Kevin M, Waldron, Ronan P, Bennani, Fadel, Eustace, Paul W, Tobbia, Iqdam
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648993/
https://www.ncbi.nlm.nih.gov/pubmed/19118499
http://dx.doi.org/10.1186/1471-2407-9-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648993/
https://www.ncbi.nlm.nih.gov/pubmed/19118499
http://dx.doi.org/10.1186/1471-2407-9-1

Ejemplares similares